<SEC-DOCUMENT>0001144204-15-029266.txt : 20150511
<SEC-HEADER>0001144204-15-029266.hdr.sgml : 20150511
<ACCEPTANCE-DATETIME>20150511161024
ACCESSION NUMBER:		0001144204-15-029266
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150511
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150511
DATE AS OF CHANGE:		20150511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		15850813

	BUSINESS ADDRESS:	
		STREET 1:		617 DETROIT STREET, SUITE 100
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48104
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v410291_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B>&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<B> SECURITIES
AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
May 11, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center">Nevada</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center">1-12584</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center">13-3808303</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction of incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Commission File No.)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(IRS Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>155 Gibbs Street, Ste. 412</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Rockville, MD 20850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices
and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>617 Detroit Street, Ste. 100</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ann Arbor, MI 48104</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Mailing Address and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code:&nbsp;(734) 332-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">N/A&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.9pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<HR NOSHADE SIZE="1" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.02 - Results of Operations and
Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 11, 2015, Synthetic Biologics, Inc.,
a Nevada corporation, (the &ldquo;Registrant&quot;) issued the attached press release that included financial information for the
three months ended March 31, 2015. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K. The information
contained in the press release is being furnished to the Commission and shall not be deemed incorporated by reference into any
of the Registrant&rsquo;s registration statements or other filings with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">(d)&nbsp;Exhibits.&nbsp;</TD>
    <TD STYLE="width: 85%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Exhibit 99.1&nbsp;</TD>
    <TD>Press Release issued by Synthetic Biologics, Inc. dated May11, 2015.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt"></P>

<HR NOSHADE SIZE="1" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>SIGNATURES</U></B> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">SYNTHETIC BIOLOGICS, INC.</TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="width: 50%">Date: May 11, 2015</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid">/s/ C. Evan Ballantyne</TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>C. Evan Ballantyne</TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Financial Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt"></P>

<HR NOSHADE SIZE="1" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 31.9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; text-decoration: underline; text-align: center"><U>Exhibit No.</U></TD>
    <TD STYLE="width: 85%; text-decoration: underline"><U>Exhibits.</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">99.1</TD>
    <TD>Press Release issued by Synthetic Biologics, Inc. dated May 11, 2015.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v410291_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 48pt; width: 243.75pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Synthetic Biologics Reports First Quarter
2015 Financial Results and Operational Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>--Initiated Phase 2 for Prevention
of C. difficile,</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>Expected to Initiate
Phase 2 for IBS-C by end of June 2015, and</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>Expanded Leadership Team as Company
Moves into Next Development Stage --</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>-- Conference Call Today, May 11,
2015, at 4:30 p.m. EDT --</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For Immediate Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><B>Rockville,
MD, May 11, 2015 &ndash;</B> </FONT>Synthetic Biologics, Inc.<FONT STYLE="color: windowtext"> (NYSE MKT: SYN), </FONT>a microbiome-focused,
clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases,<FONT STYLE="color: windowtext">
reported financial results for the three months ended March 31, 2015, and provided an operational update.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We&rsquo;ve made great progress
during the first quarter of 2015,&rdquo; said Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. &ldquo;We&rsquo;ve
advanced our <I>C. difficile</I> program into Phase 2 clinical trials, plan to initiate Phase 2 clinical trials for our irritable
bowel syndrome with constipation (IBS-C) program before the end of June, and expect to have Phase 2 data from both programs focused
on protecting the microbiome by year end. Due to the nature of these microbiome programs, the time spent in the clinic is less
than the typical drug development program, and we are positioned to create value for our shareholders at multiple points during
the remainder of 2015.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Riley added, &ldquo;We&rsquo;ve recently
expanded our leadership team with the appointment of Steve Shallcross as our Chief Financial Officer beginning June 1<SUP>st</SUP>,
and Maureen Early joining the team in the newly created position of Vice President, Commercial. We are very optimistic about the
potential of Synthetic Biologics to meet unmet medical needs while generating significant returns for our shareholders.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Clinical Programs Update</U> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Prevention of <I>C. difficile</I> infection
&ndash; SYN-004: </B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Completed Phase 1a and 1b clinical trials; reported positive topline safety and tolerability data
from both studies</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Reported positive pharmacokinetic (PK) results from both the Phase 1a and 1b clinical trials, with
supportive evidence for no active enzyme absorption into bloodstream observed</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Initiated a <FONT STYLE="color: windowtext">Phase 2a clinical trial to evaluate gastrointestinal
(GI) antibiotic-degrading effects and safety</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Presenting poster of late-breaking preclinical data for protection of microbiome at Digestive Disease
Week&reg; (May 2015)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Presenting poster of clinical data for protection of microbiome at American Society of Microbiology
2015 (June 2015)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Expect topline data from Phase 2a clinical trial (2Q 2015)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Plan to initiate a Phase 2b proof-of-concept clinical trial (2H 2015); expect topline data (2H
2015)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IBS-C &ndash; SYN-010:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Poster presentation of preclinical data
by lead principal investigator of Cedars-Sinai Medical Center at Digestive Disease Week&reg; (May 2015)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expect to submit an Investigational New
Drug (IND) application to initiate clinical trials (2Q 2015)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Plan to initiate Phase 2 clinical trials
(2Q 2015); expect topline data (2H 2015)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pertussis (whooping cough) &ndash; SYN-005:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">Presented two posters
at ECCMID 2015 (European Congress of Clinical Microbiology and Infectious Diseases) that highlighted positive preclinical data
regarding the monoclonal antibody combination, SYN-005, for the treatment and prophylaxis of whooping cough</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Seeking non-dilutive funding to support
preclinical and clinical development (ongoing)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RRMS &ndash; Trimesta<SUP>TM</SUP>:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">MRI brain scan analyses underway by University of California, Los Angeles (UCLA) to evaluate changes
in the brain that correlate with improvements seen in clinical outcomes; topline data expected from UCLA (2Q 2015)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As previously disclosed, active discussions
with a number of potential strategic partners may accelerate development of Trimesta, pending data from UCLA (ongoing)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A separate multi-center U.S. Phase 2 trial is underway focused exclusively on cognition utilizing Trimesta with a variety of currently
marketed MS drugs</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Three Months Ended March 31, 2015
Financial Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses increased
to $1.7 million for the three months ended March 31, 2015, compared to $1.1 million for the same period in 2014. This increase
of approximately 53% is primarily the result of increased employee costs, audit fees related to the additional procedures required
under the accelerated filer status and stock compensation expense for the three months ended March 31, 2015. Non-cash charges related
to stock-based compensation were $582,000 for the three months ended March 31, 2015, compared to $255,000 for the same period in
2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses increased
to $6.5 million for the three months ended March 31, 2015, compared to $2.7 million for the same period in 2014. This increase
of approximately 139% is primarily the result of increased program costs associated with expanded clinical development, manufacturing
and research activities within our pathogen-specific, microbiome-focused pipeline, including the Company&rsquo;s <I>C. difficile</I>,
IBS-C and Pertussis programs. Research and development expenses also include a $1.0 million expense for achieving the third milestone
as set forth in the Asset Purchase Agreement with Prev ABR LLC, dated November 28, 2012, related to the <I>C. difficile</I> program.
Prev ABR LLC exercised its option to receive the milestone payments in shares of Synthetic Biologics&rsquo; common stock, issued
in April 2015. Non-cash charges related to stock-based compensation were $246,000 for the three months ended March 31, 2015, compared
to $107,000 for the same period in 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other expense was $4.2 million for the
three months ended March 31, 2015, compared to other income of $1,000 for the same period in 2014. Other expense for the three
months ended March 31, 2015 is primarily the result of a non-cash charge of $4.2 million related to the change in fair value of
warrants. The increase in the fair value of the warrants was due to the increase in the stock price from the previous period. There
was no non-cash income or expense relating to fair value warrants for the three months ended March 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash at March 31, 2015 was $12.0 million
compared to $17.5 million at December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Conference Call</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics will hold a conference
call today, Monday, May 11<B>, 2015, at 4:30 p.m. EDT. </B>The dial-in information for the call is as follows: U.S. toll free:
1-888-347-5280, Canada toll free: 1-855-669-9657 and International: +1 412-902-4280.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Participants are asked to dial in 15 minutes
before the start of the call to register. Registered callers may ask to be placed in the queue for the Question &amp; Answer Session.
The call will also be webcast over the Internet at http://www.videonewswire.com/event.asp?id=102272.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An archive of the call will be available
for approximately 90 days at the same URL, http://www.videonewswire.com/event.asp?id=102272, beginning approximately one hour after
the call&rsquo;s conclusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE MKT: SYN)
is a microbiome-focused,&nbsp;clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific
diseases. The Company is developing an oral biologic to protect the gut microbiome from intravenous (IV) antibiotics for the prevention
of<I> C. difficile</I> infection and an oral statin treatment to reduce the impact of methane producing organisms on irritable
bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment
of Pertussis in collaboration with Intrexon Corporation (NYSE: XON), and a Phase 2 oral estriol drug for the treatment of relapsing-remitting
multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><I>This
release includes forward-looking statements on Synthetic Biologics&rsquo; current expectations and projections about future events.
In some cases forward-looking statements can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot;
&quot;continue,&quot; &quot;expects,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot;
&quot;estimates,&quot; and similar expressions. These statements are based upon current beliefs, expectations and assumptions and
are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the
planned Phase 2 clinical trials, expected date of data from clinical trials and the expected date of submission of IND application
for SYN-010. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially
from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ
materially from those reflected in Synthetic Biologics&rsquo; forward-looking statements include, among others, a failure to receive
the necessary regulatory approvals for commercialization of Synthetic Biologics&rsquo; therapeutics, a failure of Synthetic Biologics&rsquo;
clinical trials, and those conducted by investigators, to be commenced or completed on time or to achieve desired results, a failure
of Synthetic Biologics&rsquo; clinical trials to receive anticipated funding, a failure of Synthetic Biologics&rsquo; products
for the prevention and treatment of diseases to be successfully developed or commercialized, Synthetic Biologics&rsquo; inability
to maintain its licensing agreements, </I></FONT><I>a failure to successfully integrate new management and other factors described
in Synthetic Biologics&rsquo; report on Form 10-K for the year ended December 31, 2014 and any other filings with the SEC.<FONT STYLE="color: windowtext">
The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation
to update any forward-looking statements contained in this release on account of new information, future events, or otherwise,
except as required by law.</FONT></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics: Kris Maly, VP, Corporate
Communication, (734) 332-7800, info@syntheticbiologics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Media: Wendy Emanuel, Wellspring Communications,
Inc., (773) 255-9580, wendy@wellspringcom.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors: Michael Polyviou, EVC Group,
Inc., (212) 850-6020, mpolyviou@evcgroup.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>- Financial Tables Follow -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Synthetic Biologics, Inc. and Subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>(in thousands, except share and per share amounts)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I></I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Condensed Consolidated Balance Sheets</b></font></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31,</b></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2015</b></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2014</b></font></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>(Unaudited)</i></b></font></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>(Audited)</i></b></font></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Assets</b></font></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Cash and cash equivalents</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">12,049</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">17,525</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Prepaid expenses and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,574</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,548</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">75</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">65</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Deposits and other assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">18</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Total Assets</b></font></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">13,716</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,144</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>Liabilities and Equity (Deficit)</b></font></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15,341</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,588</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Synthetic Biologics, Inc. and subsidiaries equity (deficit)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,625</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,556</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Total Liabilities and Equity</b></font></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">13,716</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,144</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I><BR CLEAR="ALL">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Condensed Consolidated Statements of Operations <i>(Unaudited)</i></b></font></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the three months ended</b></font><br> <font style="font: 10pt Times New Roman, Times, Serif"><b>March 31,</b></font></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif"><b>2014</b></font></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>Operating Costs and Expenses</b></font></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">General and administrative</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,713</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,122</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,494</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,717</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Total Operating Costs and Expenses</b></font></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,207</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,839</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Loss from Operations</b></font></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(8,207</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,839</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>Other Income (Expense)</b></font></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Change in fair value of warrant liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,152</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Total Other Income, net</b></font></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,151</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Net Loss </b></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(12,358</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,838</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Net Loss Attributable to Non-controlling Interest</b></font></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries</b></font></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(12,358</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,838</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Net Loss Per Share - Basic and Dilutive</b></font></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.17</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.07</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Net Loss Per Share Attributable to Synthetic Biologics, Inc. and Subsidiaries</b></font></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.17</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.07</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted average number of common shares outstanding - Basic and Dilutive</b></font></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">72,673,959</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">58,324,260</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><BR CLEAR="ALL">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`9`!D``#_X0O$17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````<````<@$R``(````4````CH=I``0````!````H@```,X`#T)````G
M$``/0D```"<0061O8F4@4&AO=&]S:&]P($-3,R!7:6YD;W=S`#(P,3$Z,3(Z
M,3@@,3`Z,C@Z,34```.@`0`#`````0`!``"@`@`$`````0```D^@`P`$````
M`0```8H`````````!@$#``,````!``8```$:``4````!```!'`$;``4````!
M```!)`$H``,````!``(```(!``0````!```!+`("``0````!```*CP``````
M``!(`````0```$@````!_]C_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+#!D2
M$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_VP!#
M`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``?`*`#`2$``A$!`Q$!_\0`'P``
M`04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0`
M``%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8
M&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)
MRM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!
M`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$
M!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I
M*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W>\OH+&,-,QRQ
MPJJ,EC["JIU"^DB,EOIC.,C:'E"$CUZ'V_.HJ.48-Q5WV*@HN24G9!_:WDJS
M7ME<6JHNYG(#IU`QE23W]*O0SQ7,2RP2I+&WW71@P/XBBE.4X\SBUZE5*?)L
M[KNB2L'Q5XLT_P`):<EU>[Y))6*PP1XWR'OU[#C)[9'J!5F9S5O\47MK^WM_
M$7AR^T:.Y($4TK$KG(R3N5<`9&<9QZ5LZ'XV@U7Q%>Z#=V4FGZC;=(I7SYH'
M4KP,\8(]0<C@4`5;CXAVZZYJNFV>G372Z7;RSW-P)`JKY:Y8#/).<+]?89J]
MX.\:V/C&UN'MXGMY[=@)()#D@'HP(Z@X(_#Z9`,U_B([S:O#9>'[Z]ETV\%J
MZ6_SLV3(-^`#@?N__'A6;!\69+J]ELK?PIJ<UW%GS((_F=,'!RH7(P2!0!N:
M5X[34O%2Z`^EW%K<_9TG<RM@H6C5]I7&01NQ^%7-?\6PZ!K>C:9):/,VIS")
M75@!&=RKDCO][]*`.<B^*<MW=W5O8>%M3O3;.4D-N"^WD@9PIQG!_*K0^(&J
M&!Y/^$(UP%650ODMDY!Y^[VQ^M`%*V^*T]Y<3V]KX2U6>>!MLT<0+-&<XPP"
MY!R#U]*V=,\=QZAXK3P^^F3VUP;=)W,K8*%HEDVE<9!&[!]Q0!F7GQ1$M]-;
M^'?#]]K:0'$LT`8(">F,*Q(.#R<=#C-=!X2\9:?XOM9I+2.6&>W*B:&4<J2.
M""."."/7CH*`)M151K]L\H_=^6,$CC@G/Z5N4`%9%YIDEK(]]I`$=R2#)!G$
M<X]QT!_VAS]<U479Z[%PE9V>S+6DZI!J]A'=VYX8#<A8$H2`0#@]P01[$'O7
M)?$;3M#U;^R;+4=4?3=2DF(T^98G<%B5#*<<#G9R2,<'.,YGT%.+A)Q9RWB&
MZ\7^$[6UE\3II'B'2C,(U2>)7*M@D<E00Q4-\Q##KGWO?%&S%O;:7XTTF9[2
M^1D0NH*LZLI*D^XY!!'(;!X&*"2YH'AZ#0_@_J4Z$/<ZAI<MU-)CG#0DJOK@
M`_F6/>N0T>RN?"_AG0?'6EH7"^9#J4.\@2(964'^0]B$.#S0!U7PLNX;_P`2
M>,[RW;?!<7B2QM@C*L\Q!P>G!JCX&_Y+/XG_`-VY_P#1Z4`4=7M];N?C;J4?
MA^\@M+_RD(EF`*[?)3(Y5OY5'K=GXIM/''A(>)M2M;UFOH_(-NH&T>8F[.$7
MV]:`*W@NS\5W>L>(?^$8U*TLMMPOVC[0H._+2;<?(W3YO3K7KOABV\06NFR)
MXDO;>\O#,2DENN%$>%P/NKSG=V[T`<7\.O\`DH'C7_K\;_T;)6%KR22?%CQ,
MD2LTC:5,$5!DD_9!@#'>@#K_`(0RV+^!8H[4K]H2:3[4!G.\G@G_`(!LY'''
ML:T=#U7PW=^,=5L]+T[9J4`?[5=I`JJYW`,-P.2=WJ.=IH`Z&_M&N[<K%((9
MQ_JY=N2GKC\*PK;6[C2KC[)K"N"3A'Z@XZE3_$.1[CTKAQ,YTJD:M_=V:_4B
M3<7?H;]M?VEYC[/<1R$C.T-R![CJ*CO]4LM,CWWEPL0*EE!ZL!C.!W/(XKNI
M-5K>SUN34K4Z<'4F[)'%_#:.Y6[URXQ$UA=W`EA:WD0Q*W)8;`Q*$ADX(S@#
M-;WBW1-`U^R2TUMUC,:O-%,'"/$JXWL">B\KG/'3/:IA"<%RS5FCT,=6HUZS
MJT'>+2_)7_$R8OA=I#7%K)?ZCJNI0VO$-O>7(>-1C&,``XX'`('`SQQ6_P")
M/#UCXKTLZ;>33)$LJN3`P#!@.!R#V/I5'(/FTNQMO"O]BS3O'9?9!8^8S`.5
M*B,<XQN.0!QR2..U1Z%H>F:?X731;61KO3U66(^:P8L&9MZM@`=2P(QQC%`%
M/PKX.TKP=+=1V%S<R/>!69;AU)PF>5PH_O\`/X4_2?!>G:/XGO\`7[>:Z:ZO
M0XD21U*#>P8X`4'J!W-`$<7AW1H_'4^OI>RG4Y`(7A,B^6#Y:_+C&=VP!L9S
M@YZ5:UKPI8Z[JVE:E=2W"3:;*)85B90K'<K?-D$D94="*`.3;X3>%=1O;B1-
M3U%Y68R.J31\9)_V.F01^!]*Z+PUX0TGP-!?SVMU<F*95>9[J12$5`QSD*,#
MYCG-`%K1?"=AH6L:IJ=K+<O/J4ADF65E*J2Q;Y<`$#+'J359?#6CP>.G\0?;
M)AJ<RA/(,B[/]7MP!MSG:A/7L3T%`&7??"C0+J^FNK6:^TXS`B2*SE"H0?O`
M`J<`^G3VK:\*>']#\-VTUCI!#R9#7$CL&E?D@%B,<`A@,`#(;OF@#H*BN(8;
MB%HKB))8SU1U#`_@:32:LP.2OM!T!+A8Q=7EJ3P$C<L#_P!]*V*F3P7I]U8>
M1<7=U,O_`"S<%4*`G)&`,'/<D$\#TK/"T8X6K[6EN<5?`TJT7&5[,Z.PT^TT
MRS2ULH$@@3HB#]3ZGW-5=4T.UU=B;AI`3:S6OR$#"R[-Q&0?F&P8/UZUM*3D
M[O<ZXQ48J,=D:=,2)8WE<$YD8,<^N`/Z4BAES`;B'8LK1L&5PP`/*D'!!['&
M#WP3@@\TVQLTL;<PHS,&EDE);'WG<N>G;+''MZT`.:W1KR.Y);?'&\8';#%2
M?_01^M34`4#IBM=Q3-.Y2&=KB*/`^5V1D(SC)7YV..N3UQ@"_0!GZ=I*Z:(8
MXKB<V\$(@AA+?*J#&,^K#&,^GODFQJ%E'J.FW5C,S+%<PO"Y0X8!@0<9[\T`
M6*IQZ>(+Z:XBF=%GD$LT>`0[!`@Y/085>!W`Z<@@%RJEG8)9SSR(YQ*<[``J
M@[F8G`XW$L<MC)`7.2,D`__9`/_M$GQ0:&]T;W-H;W`@,RXP`#A"24T$)0``
M````$``````````````````````X0DE-!"\``````$K;`0$`2````$@`````
M`````````-`"``!``@`````````````8`P``9`(````!P`,``+`$```!``\G
M`0!L;'5N`````````````#A"24T#[0``````$`!D`````0`!`&0````!``$X
M0DE-!"8```````X`````````````/X```#A"24T$#0``````!````'@X0DE-
M!!D```````0````>.$))30/S```````)```````````!`#A"24T$"@``````
M`0``.$))32<0```````*``$``````````CA"24T#]0``````2``O9F8``0!L
M9F8`!@```````0`O9F8``0"AF9H`!@```````0`R`````0!:````!@``````
M`0`U`````0`M````!@```````3A"24T#^```````<```________________
M_____________P/H`````/____________________________\#Z`````#_
M____________________________`^@`````________________________
M_____P/H```X0DE-!`````````(``3A"24T$`@``````!``````X0DE-!#``
M``````(!`3A"24T$+0``````!@`!````!CA"24T$"```````$`````$```)`
M```"0``````X0DE-!!X```````0`````.$))300:``````-)````!@``````
M```````!B@```D\````*`%4`;@!T`&D`=`!L`&4`9``M`#$````!````````
M``````````````````$``````````````D\```&*````````````````````
M``$`````````````````````````$`````$```````!N=6QL`````@````9B
M;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG````````
M``!,969T;&]N9P``````````0G1O;6QO;F<```&*`````%)G:'1L;VYG```"
M3P````9S;&EC97-6;$QS`````4]B:F,````!```````%<VQI8V4````2````
M!W-L:6-E241L;VYG``````````=G<F]U<$E$;&]N9P`````````&;W)I9VEN
M96YU;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R871E9`````!4>7!E
M96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S3V)J8P````$`
M``````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`````
M`````$)T;VUL;VYG```!B@````!29VAT;&]N9P```D\````#=7)L5$585```
M``$```````!N=6QL5$585`````$```````!-<V=E5$585`````$```````9A
M;'1486=415A4`````0``````#F-E;&Q497AT27-(5$U,8F]O;`$````(8V5L
M;%1E>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T````/15-L:6-E2&]R
M>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0````]%4VQI8V56
M97)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N=6T````115-L
M:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S971L;VYG````````
M``IL969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T;&]N9P``````
M```+<FEG:'1/=71S971L;VYG```````X0DE-!"@```````P````!/_``````
M```X0DE-!!0```````0````'.$))300,``````PP`````0```*````!K```!
MX```R*````P4`!@``?_8_^``$$I&248``0(``$@`2```_^T`#$%D;V)E7T--
M``'_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48
M$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+
M"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!K`*`#`2(``A$!`Q$!_]T`!``*_\0!
M/P```04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0``````
M```!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3
M(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T
M-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=7
M9W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!
MD12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T
M9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7
MI[?'_]H`#`,!``(1`Q$`/P#U5))))2DDDDE*22224I))))2DDDDE*22224I)
M)))2DDDDE*22224I))))3__0]522224I))))2DDDDE*22224I))))2DDDDE*
M22224I))))2DDDDE*22224__T?54DQ(`D\*BSJ-N386X=.^MI@W/.UO]AL.<
MY)3?25`V]:9N+L>BYLG:&6N:Z.W\Y5L_Z:G5U7&=D?9;@_&R"2&5W#;OCO19
M[JK_`/K=GJ)L)<5T)"M[C**\XY#727]TB7X-Q))5>I]0Q^F=/R.H9,^CBUNL
M>&B7$-'T6#3WO^BQ.6-I)<+_`,]OK9^S_P!N?L*H]'C?(R)MV3L]71N[9N_[
MK_R_YG]*K;/K\T=4Z?7?C"KI'5ZVOP\YSB'!SHK=1DT%FQEE&3^@OV7O9^FH
MN_F_424]>DN;ROK7<?K33]7.EXS<IX`=G9#GEK:&Z/L]K:W[W5U.K_/9^FR<
M>G_2>G7^J'U[K^L.39AY..W#RMGJT,;87BQ@_G1N<RK]+5[?9_H_^+L24]8D
MN0_YX]<R,SJN'TSI+,R[IF2RD,%X875N.0UU[O58UK-CL>O]'[_YU5*/KU]:
M<G,R,#&Z`RW-Q/Z10,IH+.VKGUMK=S_@WO24]TDN;Z/]:<W.^L=_0\K#;C/Q
ML5F18X6;W"QS,6RR@MV;/T;\M[/4;9_@E+JGUIOP?K/C=#;C-LKR,9^0;R\A
MP+695GI^GL=_W#^EO_PB2GHDEPW3/KO];.JX@S.G_5YF303M+VY36C<`"YNV
MUE;_`&[E;R?K+]<\?'9D.^K@#6U/MR2<ID5['6:<'?\`H*V7>W_2)*>N27'=
M#^N'UEZP_&NHZ&T].NM%=N8W(:0QH=LNL]*QE=C_`$OZJ73O\8=-GU:R.N]0
MQA0:LC[-3CU/WFQYKKO8&OL;3L_G'^I_HZJO424]BDN&M^NWUKP\5O5NH=`%
M72'02X7#U6,=]!]C7@.;_P!>HQ_^$]%=CT_/Q>I8-&?B/]3'R6-LK=Y.$P[]
MU[?HO8DI_]+U'(K=9CVUM^D]CFCXD0JO1S^IM:6EI&L'_-/_`$V.5Y974NF9
M1R#G8+YO@;J7&`0WZ/I/_P`'9_QGZ*W_``B9EG.,;C#CUUC='A\$$UTMU4+*
MQ<?+I=1DUMMJ?RUP_$?NN;^:]95'UEH;9]GSV.QL@<M<T@_'TS[_`/MGUZ_^
M$5P]:Z;Z=CVW!_IL=8Y@!W;6\Z.V_P!5#'GQS($9>HFN$^F?%VX4>[$:\0%:
M[U5-7!SG874OV)FY`ML>WU,%[R?5LK_2;J[?;LLLQVT_SV_])_A/?[["_67)
MP,7H6;=U+'LR\$5[<FBH`O-;R*K")?3M]-K_`%'V>JSTV?I%SF1DCK_ULP+,
M%[F'ISMQ:YKBTU_2LLWU-<VCU8]#9?9_H/\`A]G6]0RJ,3"MR,AN^EC?>T09
M!.R/TA97^=_A';%+*,XR(G'A.E>,2RRG@R8\67#D&3W(GW*_0R1EP_U?F^9\
MY9T]F!T5W6_JU]9;L;'8SUAT_*>PN#XW/Q7UAQQ_M>[]'Z?V6[UK?\)_A5L9
MG_93_BY/4NI,:,NBF[)KL:(!?C&UGJ-9/\WF4U;;&?N7^S_!J_A?4WZD]1:W
MJ-72JAO<\;22&2QSJGM]&JQV+Z>]COYO]"];M]>"]@Z/94#1D8]C?1`BOT6>
MG195[=NSVY#&L:U!8\W_`(MNFTU]&=UAY-N;U.RQUUKR7.VUV64MKWN)<[<]
MMF18_P#PEMW]1<CT#HV9D_5/]M]*);U?HV:^VC:)=94*L=UM!`]UG+WLK_PG
MZ?&_[5+T^JCIW0NF&O&J]##Q@YS::P7:N<;'-K;JYS[+;/\`/0?J_A]*P<6[
M%Z9AG`;7<?7QC$MM+*W27,?=6[?0:'?H[7_]N>HDIY7_`!<YC,_KG7\]C=C,
MPT7M:3NC>[)=MW#Z2)]5?_R@_6+X?]^8NEP^F=$Z-F'[#B-QKNI.(>ZH0'%@
MLR/<)VL;[K=NQ'Q>B]*Q,_(ZCC8[:\S+_I%PG<_6?=KY)*>%NZ5D]5_QB]7Q
M<;.NZ:]M3;#D8Y(>0*\)GHF"S]&[U-__`%M!NZ7D]*^O.#BY.==U*QV'=8,C
M()+P'4=09Z(ES_T;/3W_`/7%VF(SHHZ[=G48;J\W*+\9W4"/;:ZG8V[';[R[
M=7]E_/IKW_9;/35CJ'2NB')/6\ZAAR,2E[?M)W%S:0VWU6PW_@[[_P`W\])3
MYO\`5#$KNZ,Q[OK._H9#R/L;;:ZP=&?I]EKV/_2+NV>DWZGY5574?VOZ6-D,
M=G;VV%[MMCCO?6Y[=S-VQ5<#ZH_4W,8^.CLI=2[TWUV$%P,-=_@;KF?G?O[U
MK5=-Z/TO#9TK'QA5B9KWU&EDEI-C+++=\NW;7UUO24XO^*__`,2=7_'7?]65
MY_11;_S*IS=AMQ\/JV[(8.-KL?%:QS_S6M<_]7]W_<A>Q=-Z9T_I.(,3I]+<
M;&:2X5MF`7>YY]Q*H]`PNBUX%N+T_IQQ<#)`M++&@UW,M;Z?J;2^[^<IJ;ZE
M-WIV_P"FI24AZI]<_J_B]%?U*O(IS&N9-6,U[0^PG_!.K=[ZO^']6O\`0?X5
M:/0\QV?TG%S78WV+[16+!C$@EK7>ZN=K6?39^D^BL;*^J7U,Z2#U-W2F.-;F
M^T2Y@)<&M=Z5]GV2JNN=WJ6^G32NCHN;?17>T%K;6AX!B0'#=KM+FI*?_]/U
M5))))37R\>O(J-=U%>0SG9:`6S_::]9]'U<Z6VP7?8VT6#_16V`1^[M8:F;/
MY&Q;"2!C$FR`3Y(,0=P"AQL3&Q6N;C5,I:]V]S6`-!=`;NVM_JI\G'IRJ747
M-W5OB0"6G0[FEKV%KV.:X?2:BI)Q))LZJ``%`4/!%C8M&+5Z-#=K)<XR2XES
MR7V/>]Y<][WO=NW/4C34;FWELVL:YC7>#7ECK&_VG4UJ:2"4=]%612^B]HLJ
MM:6/8>"TZ."CBXE&(PLI!&]V][GN<][G0&[K+;7/ML=L:QGO?_-L]-&224@R
ML+'R_3-P=NI=OK<Q[ZW`D%A]]+JW_1<CI))*:M?3,*K+=F,KBYVXSN<6@OCU
M7UTEWHUV6[?TME=>^S\]6+*V6,=78T/K>"U['"00='-<T_2:Y2224UL/IV)A
M;_L["#:0;'/>^QSMH]-FZRYUC_8P;46RFJUU;K&[G4NWUGP=M=7N_P`RQZ(D
MDI2K8?3L/!+CC5[-X:TRYSH8S=Z5-?J.?Z5%6]_I45?H:O\`!L5E))2+)QJ<
MJKTK@2V0X%KG,<"#+7,MJ<RQG]AZ?'QZ<:BO'H8*Z:FAK&#@`(B22G__U/54
MDDDE*22224I))))2DDDDE*22224I))))2DDDDE*22224I))))2DDDDE/_]7U
M5))))2DDDDE*22224I))))2DDDDE*22224I))))2DDDDE*22224I))))3__9
M.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S
M`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`
M4P`S`````0`X0DE-!`8```````<`"`````$!`/_A#]!H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-
M,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^#0H\>#IX;7!M971A('AM;&YS.G@]
M(F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835`@0V]R92`T+C$M
M8S`S-B`T-BXR-S8W,C`L($UO;B!&96(@,3D@,C`P-R`R,CHT,#HP."`@("`@
M("`@(CX-"@D\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N=S,N;W)G
M+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@T*"0D\<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C
M+V5L96UE;G1S+S$N,2\B('AM;&YS.GAA<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87`O,2XP+R(@>&UL;G,Z>&%P34T](FAT='`Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN<SIP:&]T;W-H;W`]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B('AM;&YS.G1I
M9F8](FAT='`Z+R]N<RYA9&]B92YC;VTO=&EF9B\Q+C`O(B!X;6QN<SIE>&EF
M/2)H='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R(@9&,Z9F]R;6%T/2)I
M;6%G92]J<&5G(B!X87`Z0W)E871O<E1O;VP](D%D;V)E(%!H;W1O<VAO<"!#
M4S,@5VEN9&]W<R(@>&%P.D-R96%T941A=&4](C(P,3$M,3(M,3A4,3`Z,C@Z
M,34K,#$Z,#`B('AA<#I-;V1I9GE$871E/2(R,#$Q+3$R+3$X5#$P.C(X.C$U
M*S`Q.C`P(B!X87`Z365T861A=&%$871E/2(R,#$Q+3$R+3$X5#$P.C(X.C$U
M*S`Q.C`P(B!X87!-33I$;V-U;65N=$E$/2)U=6ED.C-$,$$Q-#%$-4$R.44Q
M,3$Y0D4S041#13A",C)"-C8R(B!X87!-33I);G-T86YC94E$/2)U=6ED.C-%
M,$$Q-#%$-4$R.44Q,3$Y0D4S041#13A",C)"-C8R(B!P:&]T;W-H;W`Z0V]L
M;W)-;V1E/2(S(B!P:&]T;W-H;W`Z24-#4')O9FEL93TB<U)'0B!)14,V,3DV
M-BTR+C$B('!H;W1O<VAO<#I(:7-T;W)Y/2(B('1I9F8Z3W)I96YT871I;VX]
M(C$B('1I9F8Z6%)E<V]L=71I;VX](C$P,#`P,#`O,3`P,#`B('1I9F8Z65)E
M<V]L=71I;VX](C$P,#`P,#`O,3`P,#`B('1I9F8Z4F5S;VQU=&EO;E5N:70]
M(C(B('1I9F8Z3F%T:79E1&EG97-T/2(R-38L,C4W+#(U."PR-3DL,C8R+#(W
M-"PR-S<L,C@T+#4S,"PU,S$L,C@R+#(X,RPR.38L,S`Q+#,Q."PS,3DL-3(Y
M+#4S,BPS,#8L,C<P+#(W,2PR-S(L,S`U+#,Q-2PS,S0S,CLT1#,X,$(Y1#@V
M0T4P,41",C8X1CDW,#9$1$5!0C)!,R(@97AI9CI0:7AE;%A$:6UE;G-I;VX]
M(C4Y,2(@97AI9CI0:7AE;%E$:6UE;G-I;VX](C,Y-"(@97AI9CI#;VQO<E-P
M86-E/2(Q(B!E>&EF.DYA=&EV941I9V5S=#TB,S8X-C0L-#`Y-C`L-#`Y-C$L
M,S<Q,C$L,S<Q,C(L-#`Y-C(L-#`Y-C,L,S<U,3`L-#`Y-C0L,S8X-C<L,S8X
M-C@L,S,T,S0L,S,T,S<L,S0X-3`L,S0X-3(L,S0X-34L,S0X-38L,S<S-S<L
M,S<S-S@L,S<S-SDL,S<S.#`L,S<S.#$L,S<S.#(L,S<S.#,L,S<S.#0L,S<S
M.#4L,S<S.#8L,S<S.38L-#$T.#,L-#$T.#0L-#$T.#8L-#$T.#<L-#$T.#@L
M-#$T.3(L-#$T.3,L-#$T.34L-#$W,C@L-#$W,CDL-#$W,S`L-#$Y.#4L-#$Y
M.#8L-#$Y.#<L-#$Y.#@L-#$Y.#DL-#$Y.3`L-#$Y.3$L-#$Y.3(L-#$Y.3,L
M-#$Y.30L-#$Y.34L-#$Y.38L-#(P,38L,"PR+#0L-2PV+#<L."PY+#$P+#$Q
M+#$R+#$S+#$T+#$U+#$V+#$W+#$X+#(P+#(R+#(S+#(T+#(U+#(V+#(W+#(X
M+#,P.T,U,D5%,30W-3<Y0C,S03E&,#`T,S<U-38T,#8Q-D1$(CX-"@D)"3QX
M87!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)U=6ED.C<T,D4X
M-T0Q-3DR.44Q,3$Y0D4S041#13A",C)"-C8R(B!S=%)E9CID;V-U;65N=$E$
M/2)U=6ED.C<T,D4X-T0Q-3DR.44Q,3$Y0D4S041#13A",C)"-C8R(B\^#0H)
M"3PO<F1F.D1E<V-R:7!T:6]N/@T*"3PO<F1F.E)$1CX-"CPO>#IX;7!M971A
M/@T*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@/#]X<&%C:V5T(&5N9#TG=R<_/O_B#%A)0T-?4%)/1DE,10`!
M`0``#$A,:6YO`A```&UN=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94
M`````$E%0R!S4D="```````````````!``#VU@`!`````-,M2%`@(```````
M````````````````````````````````````````````````````````$6-P
M<G0```%0````,V1E<V,```&$````;'=T<'0```'P````%&)K<'0```($````
M%')865H```(8````%&=865H```(L````%&)865H```)`````%&1M;F0```)4
M````<&1M9&0```+$````B'9U960```-,````AG9I97<```/4````)&QU;6D`
M``/X````%&UE87,```0,````)'1E8V@```0P````#')44D,```0\```(#&=4
M4D,```0\```(#&)44D,```0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q
M.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="
M($E%0S8Q.38V+3(N,0``````````````$G-21T(@245#-C$Y-C8M,BXQ````
M````````````````````````````````````````````````````````````
M``!865H@````````\U$``0````$6S%A96B``````````````````````6%E:
M(````````&^B```X]0```Y!865H@````````8ID``+>%```8VEA96B``````
M```DH```#X0``+;/9&5S8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H
M```````````````6245#(&AT='`Z+R]W=W<N:65C+F-H````````````````
M`````````````````````````````````````````````&1E<V,`````````
M+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@``````````````+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@````````````````````````````!D97-C````````
M`"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M```````````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0``````````````````````````````````=FEE=P``````
M$Z3^`!1?+@`0SQ0``^W,``03"P`#7)X````!6%E:(```````3`E6`%````!7
M'^=M96%S``````````$````````````````````````"CP````)S:6<@````
M`$-25"!C=7)V````````!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!`
M`$4`2@!/`%0`60!>`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`
ML@"W`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K
M`3(!.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!
MT0'9`>$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8
M`J("K`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#
ME@.B`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V
M!,0$TP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&
M%@8G!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9
M!ZP'OP?2!^4'^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)
M9`EY"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1
M"VD+@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-
MC@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L
M$`D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02
MHQ+#$N,3`Q,C$T,38Q.#$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X
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M-C<V<C:N-NDW)#=@-YPWUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[
M:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G
M02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&
M\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"
M34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3
MJE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI6
M6J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]A
MHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL
M:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9P
MX'$Z<95Q\')+<J9S`7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,
M>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!
M:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^
MBF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.3
M39.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)
MG/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJF
MBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!U
ML.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[
M+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(
MQD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1
M/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*
MW1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+H
MO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"
M]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____;`$,`
M`@$!`@$!`@("`@("`@(#!0,#`P,#!@0$`P4'!@<'!P8'!P@)"PD("`H(!P<*
M#0H*"PP,#`P'"0X/#0P."PP,#/_;`$,!`@("`P,#!@,#!@P(!P@,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_`
M`!$(`&X",P,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&
M!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4
M,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)
M2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.D
MI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R
M\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U
M$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)
M(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JR
ML[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_
MV@`,`P$``A$#$0`_`/W\HHHH`****`"C-9VK>,-)T`D7^J:=9$<D3W*1X_[Z
M(K-OOBYX8T[PU?ZS-KVF+I6F?\?-TLZM%&>PR,Y8]@,DY``R145*D:<'4J.R
M6K;T27=LNG3G4DH4U=O1):MOLD='FBN%T#]IGX>>)[.WFM/&OAG-RH=(I=1B
MAF`*[L&-V#`@=01D<^E=CIFLV>MV_G65W;7D6<;X95D7\P:Y\+F&%Q*OAZD9
M_P"%I_DSHQ.`Q.'=L13E#U37YHLT49HS76<@449HH`****`"BBB@`HHHH`**
M**`"BF7%Q'9V\DTTB111*7=W8*J*!DDD]`!WKQ?QS_P4?^`7PWNIK?6/C#\.
M[>ZMSB6"+7(+B:,Y`P4B9F!Y!P1G'/3F@#VNBO%?!7_!1SX!_$6[AMM'^,7P
MZN;JXQY4$FNV\$TA]`DC*Q/'3&?:O9K.\AU&TCN+>6*>"90\<D;!D=3T((X(
M/J*`)**JZKKMCH4:/?7MI9)(<*T\JQACZ#<1FJ/_``L/P_\`]!S1_P#P-C_Q
MH`V**AT_4[;5[59[2X@NH'R!)$X=#CKR.*FH`***S]3\6:5HMR(;W4]/M)B-
MP2:X2-L>N"<XH`T**Q_^%AZ!_P!!S1__``,C_P`:EO/&VBZ?<-#<:OI<$R8W
M))=1JRY&>03Z4`:=%9VG>,-(U>[6WM-5TVZG<$B.&Y1W..O`.:T:`"BBJ>K>
M(=/T'R_MU]9V7FYV>?,L>_&,XW$9QD?F*`+E%94/CW0KF9(X]:TF221@JJMW
M&68GH`,\FGW_`(RT?2KM[>ZU73;:>/&Z.6Y1'7(R,@G(X(/XT`:5%8__``L/
MP_\`]!S1_P#P,C_QH_X6'X?_`.@YH_\`X&1_XT`;%%8__"P_#_\`T'-'_P#`
MR/\`QH_X6'X?_P"@YH__`(&1_P"-`&Q16;8^--&U.Z2"VU;3+B>0X2.*Z1W;
MC/`!R:;=>.-$L;F2&?6-+AFB8JZ/=QJR$=B"<@T`:E%4-,\6:5K5R8;+4]/N
MY@N[9#<)(V/7`.<5?H`***H:GXLTK1;D0WNIZ?:3%=VR:X2-L>N"<XH`OT5E
MVOCC1+ZYCA@UC2YII6"HB7<;,Y/8`')-6-5\2:=H+(M]?V5D9<E!/.L9;'7&
MXC-`%RBL?_A8?A__`*#FC_\`@9'_`(T?\+#\/_\`0<T?_P`#(_\`&@#8HK'_
M`.%A^'_^@YH__@9'_C1_PL/P_P#]!S1__`R/_&@#8HK-A\9:/<VD]Q'JNFR0
M6VWSI%N4*1;CA=QS@9/`SUJ'_A8?A_\`Z#FC_P#@9'_C0!L45C_\+#\/_P#0
M<T?_`,#(_P#&C_A8?A__`*#FC_\`@9'_`(T`;%%8_P#PL/P__P!!S1__``,C
M_P`:/^%A^'_^@YH__@9'_C0!L452'B33CI1OQ?V1L5.#<>>OE#G'WLXZ\=>M
M5/\`A8?A_P#Z#FC_`/@9'_C0!L45#8:C;ZK:)<6L\-S!)G;)$X=&P<'!'!Y!
M'X5-0`44,P12S$!1R2>`*\?^('_!0/X&_"R\EM=?^+GP\TZ\@#&2V;7;9[A,
M=08T<N#Z#&21@9-`'L&:*\/\$_\`!2W]G[XAWD=OI7QC^'DMS,2L<,^M0VLD
MAR!A5E922<\`<GMWKVK3]1M]6LHKFTGANK:=0\<L3ATD4]""."/<4`3449HH
M`****`"BBO)/VJ_C++\/?#L6DZ;*8M5U9&S(IPUM#T+#T9CD`]L,>H%-*XFR
M7XR?M3Z7\.;B73M-C35M6C^5P&Q!;GT9AU8?W1^)!KP#Q9\<?%_Q$NC'/JEX
M$E.%M;/,4?TVKRW_``(DUR^BZ//K^IQ6L`S)*>IZ*.Y/M7T)\#_@3;SQ"9U*
M6L9VRS8Q)<-W4>B_YZY-:62)NV>0>'/@KK7B295$1C=^=@4RR?7"_P!37HGC
MS]D&_P#C;X;TG3M<EO\`3K?2$V6PL98X+<9ZN]N=RF0YY8;2>^:^B]*T>UT.
MT$%I;Q6\2_PH,9]R>Y]S5FO,S7+<+F.&EA,;#GIRW6J_)IGH9;F.)R_$1Q6$
MFX3CLU;]3X8\1_\`!+_6-.U..&QOC>VTK;1<><H$7H74KD#/]W=]:R;K_@G5
M\0_!MR;O1KN19X^DEI<+'(/H0ZM^0K[]HK\IJ>"&1.4ITJM6%W=6E'W?)7BW
M;U;?F?H5+Q<X@BE&<HR76\;W]=?^!Y'P'#XW_:#^!3H)]4U2[MHSCR]4C-PD
M@]-\RY_[Y>O5K+_@HZOPY^&_AK5_B'X>N[:?7K^[LRVEQ$I$L"P'S=CMR"9L
M<.3\IP#R!]1R1K*C(RAE88((R"/2N&^*?[.'A/XNZ#%I^I:<D$=L9&@:U`A\
MII-N\[0-C$E5SN4]*^EX.X-QV39BIXC,)U\+9KDDG=/2S3YFM.R2^9PYGQ=E
MV:4XPQ>"A3E>[G37*VK/=*W6V]R?X0?M"^"_CQIANO"GB&PU;8NZ2!&,=S"/
M]N)L.H]R,'L:[7-?!'QF_P""8NN_#[4_[?\``6HW27-FQEAETYF@NH".X0'/
MMF-L_P"S4?P?_P""DWC7X(:G'HOQ6TN;7M+1_)75[6,)=PX./G7A9,8Z'8_4
MDL>*_6*F5*I'VF#GSKMU_K[CQ:O#\*T'5RVI[1?RO22_S_#T/OO-%<[\,OBK
MX=^,?A2'6_#.K6FL:;/P)86.4;NKJ<,C#^ZP!Y'%=%FO(E%Q=I*S/FIPE"3C
M-6:Z,****DD****`"O)_VUOVP?"_[#'[/FK_`!`\5&6:VLBMO96,+`3ZI=N#
MY5O&3P"VUB3SM1';!VXKUBOQO_X.G_B%J$GB_P"$7A-9'CTN&SO]6>,.=L\S
M/%$I9?5%1\'_`*:M30'PG^VQ_P`%,/BS^W;XFN9_%WB&YM/#ID)M/#FG2-!I
M=HH.5!C!_>N/^>DNYNN"!@#P_P`-^$=6\97YM-'TS4=5NL9\FSMGGDQC.=J@
MGH#6K\&O"NF^.OB]X4T/6+PZ=I&LZQ:6-]=;U0VT$LZ)))N;@;58G)X&*_JM
M^#?P1\)?L]^`K'PQX*\/Z7X;T/3XUCBM;*`1AL`#>Y^])(<99W)9B222235-
MV`_DWU?1+WP_>FVO[.ZL;A1DQ7$31..<=&`/4'\J]B_9`_X*%_%C]A_Q1;WW
M@7Q3>V^F)('N=#O':XTF^&<LLD!.T$]-Z;9!DX89-?TL_'O]F_P-^T_X$NO#
M7CSPSI7B32KJ-DVW4`:6W)&-\,GWXG'4.A#`CK7\W'[27_!.CXG?!3X_^,?"
M6D^`_'OB'2-`U:XL[#4[;0;F>*_MED/DRAXXRA+1[2=O`)([4D[@?LS<:MX#
M_P""_?\`P3<U&*QBCT3Q%!(1'%<$22^&];ACW(=P&6@</MW@`M%(PPK@A?P`
M\?\`@/6/A;XXU?PWK]A/I>MZ#=RV-]:3#$EO-&Q5T/T(/(X/49%?J3_P;;^$
M/B7\$_VH/&N@^)/!OC3P[X:\2^'/M+2ZEH]S:6S7EM<1"(;I$5=WESW'N?SK
MJ/\`@Y`_X)VG4+.']H#PI8YFMEBL/%\$29+IQ';WQ_W?EB?V\H]F-*X'F?\`
MP;H?\%#3\)/BG+\$/%-\5\.>-;@S^'I96RMCJ9`!@!/1+A0`!T\U5`&9&-?M
M_7\A6F:E<:-J-O>6D\MM=VDJS031,4>%U(*LI'(((!!%?TI?\$D/V^;;]OK]
ME/3]7O;B(^-_#6S2O$UNN%8W`7Y+D*.B3J-XP``PD4?<IM`>X_M!?'3P_P#L
MS_!?Q)X[\477V70_#-D]Y<$8WRD<)$@)`,DCE449&6<"OY>OVL?VF/$'[7_[
M0?B;XA>)I2VH^(+HR1P!BT=A;CY8;>//\$<851W."3DDD_>W_!Q?_P`%#!\7
MOBM%\$_"U\)/#?@BX\_Q!+"WRWNJ`$>02#ADMU)!'_/5G!&8P:_.7X3_``LU
MWXW?$K0_"'AFPDU/7_$5Y'8V-M'P9)'.!D]%4<EF/"@$G`%"0'UY_P`$-_\`
M@GA_PVM^TRFO^(['S_AW\/I(K[4UE3,6IW1)-O9\\,I*[Y!R-B;3CS%-<1_P
M6N54_P""HOQ<"@`+J%J`,8Q_H-M7[[_L+?L@Z'^PY^S/X=^'VB>7.^GQ>?JE
M\$VMJ=](`9[@@\@%@`H.=J*B\[:_`G_@MC_RE'^+O_80M?\`TAMJ$!X)\"_C
M5X@_9S^+_AWQQX6O#8Z_X9O4O;23&5)'#(X_B1U+(R]U9AWK^GS]B[]J_P`/
M_MK_`+./ASXA^'66*#5X=EY9F0/)IEVGRS6[X[JW0D#<A1L885_*OFON3_@A
MG_P49/[%G[1H\,^)=1,'PX\?S1VNH&5_W.E7GW8+SGA5Y\N0\#8P8Y\M:&@/
MZ&*_('_@ZS_YH-V_Y&'_`-Q=?KZKAU#*05;D$<@U^07_``=:?\T%_P"Y@_\`
M<720'YD?L<'_`(R[^%?;_BL-(_\`2V&O>/\`@O2?^-L/Q6_[A'_IGL:\'_8Y
M_P"3N_A7_P!CAI/_`*6PU_23\6_^"<GP.^/'Q"U#Q9XQ^&GAOQ!XCU;R_M=_
M=1N99_+B2)-Q#`?+&B*..BBFP/Y;Z*_IM_X="_LT?]$<\'_]^9/_`(NOQ!_X
M+6?!7PI^S[_P4)\5^%O!>AV/ASP_966GR06-HI$4326D3N1DD\L23[FA,#Y0
MHKZ(_P""3_PM\/?&O_@H5\-/"WBO2;37/#VKWMQ'>6-R"8KA5M)W`8`@\,JG
MKU%?O+_PZ%_9H_Z(YX/_`._,G_Q=%P/PY_X(G9'_``5'^$70_P#$PNO_`$AN
M:X__`(*@X_X>*?&GCKXPU'_T>U?T*_"[_@FQ\"?@IX^TWQ3X4^&/AK0_$.D.
MTEG?6T;B6W9D9"5RQ'*LP^AK^>K_`(*@_P#*13XU?]CAJ/\`Z/:A,#Z0_P"#
M:;/_``\3O>G_`")]_P#^C[6OWUK\"O\`@VE_Y2)WO_8GW_\`Z/M:_?6DT`5^
M!7_!RSG_`(>)V73_`)$^P_\`1]U7[ZU^!7_!RU_RD3LO^Q/L/_1]U0D!\W_\
M$OL?\/%/@MQT\8:=_P"CUK[O_P"#J?\`Y'_X,'UT_5?_`$9:U\(?\$OO^4BG
MP5_['#3O_1ZU]W_\'4__`"/_`,&/^P?JO_HRUIO<#\F:*U/!-G%J/C/2+>=%
MEAGO88Y$;HRF100?PK^EG_AT+^S1_P!$<\'_`/?F3_XNFW8#^9*BOZ;?^'0O
M[-'_`$1SP?\`]^9/_BZ/^'0O[-'_`$1SP?\`]^9/_BZ5P/Q1_8TR/^"3_P"V
MAD?]"1_Z>)J^0*_J1\,_\$Y/@=X-^'WB?PII?PT\-V7ASQG]E_MNPCC<0ZE]
MEE,MOY@W9/ER$L,$<FN;_P"'0O[-'_1'/!__`'YD_P#BZ$P/YDJ*_=+_`(+&
M_P#!.3X'?`;_`()P_$;Q9X/^&GAOP_XCTK^S/LE_:Q.)8/,U2TB?:2Q'S1NZ
MGV8U^%M-`%%?NE_P1R_X)R?`[X\_\$X?ASXL\8?#3PWX@\1ZK_:?VN_NHG,L
M_EZI=Q)N(8#Y8T11[**^F_\`AT+^S1_T1SP?_P!^9/\`XNDF!^?/AD?\<K'B
M'T_M!/\`U)K>OR8K^A7_`(+#?!7PI^S[_P`$8?B9X6\%Z'8^'/#]D^F206-H
MI6*)I-;LG<C))Y8DGW-?SU41`_H]_P"""W_*)[X4]?\`F+_^GB^KU#]O3]O7
MP7_P3[^"\OBOQ9*]W?7;-;Z-HT$@6ZUBX`!V)G.U%R"\A!"`C@LRJWEW_!!J
M58?^"37PK=V5$0:N6).`!_;%]R:_%/\`X*H_MN7G[=?[7GB'Q-'=S2>%-*E;
M2O#5L6.R&RC8A90O9YFS*W?YPN2%&$D`O[;/_!57XP_MS:W=IXC\1W6C^%9'
M;[/X;TF5K?3XD.<"0`YG8`\M*6ZG`4';7S=CL*]]_P""<G[!'B#_`(*%_M#V
MO@[2ISI>CV<7V[7=6,>]=.M`P!('1I7)"HO<G)PJL1_03^S5_P`$T_@E^RCX
M;M+'PI\/]`>\M@"^KZE:1W^J7#C&7:XD4L,D9VIM0'[JKTIWL!_+SS@5[/\`
MLD?\%`?BO^Q)XEBOO`/BN^LK'S`]SHURQN-*OAGD26[';D\C>NUQDX8$U_1O
M\?\`]@GX/?M/>&[C3?&?P^\-:D+A<+>1V:6U_`<8#1W$8652!CHV#@9!'%?S
M^_\`!5/_`()U:A_P3G_:&708KNXU?P?X@@:_\/:E.`)I8@0LD,NT!?-B8@$J
M`&5D;"[BJC=P/W+_`."9_P#P4I\*_P#!1KX12ZKIT":)XMT0K%KVA/,)'M&;
M.V6-L`O`^#M;`((93R`3]*U_,?\`\$HOVIKW]D?]NKP+XBBN6@T?5;Z/0M<0
MG$<UC=.L;EO^N;%)A_M0KVR*_IPI,`HHHI`%?&_[4.N2:W\;-8#LQCLREM&I
M_A"H,C\6+'\:^R*^,OVE],DTKXW:\C@D32K.I[$.BM^F<?45=/<F19^#.C!;
M"XO2N99I/)3UP,9Q]2?_`!VOKC0=)30=%M;.,`+;QA..YQR?Q.3^-?+/PEG"
M^$H&0#=%*^?KNS_+%?5ME=I?V4,\9!CG19%/7((R*)A$EHHHJ"@HHHH`****
M``\UYM\=?V7O#/QWTN9=0M(K;4I$VB\BB4LW'`D4\2+['D=B*])HK2E5G3DI
MP=F;4,14HS52E*S78_,7QU\)/B/^P!\3/[<\)W4]K$QW-$FZ:SU&('E2I^^O
M/*G#IG(/((^ROV/_`-N'PW^U7H@MT,>C^*[2,/=Z5)("7'>2$G[\?KW7(![$
M^K^//`>E_$GPS<:3J]JMS:7`^CQ-V=#_``L.Q_ID5^8/[2?P8U#]GSXMS:UX
M2U"[M]1T.?[2D\4,EM,!U$H1U!!QG<,%6!)&03GZ"DZ>90<:BM477OZ_UZ'V
M>'G0SNFZ=9<M:*TDMGZ_UZ=3]5\CU%%?-?['O_!1+PW\>?#>G:9XCO+30_&K
MS)9-:G(CU*1N%DAZ\,>JG[I]1@U]*9KP:^'J49N%169\AC,%6PM1TJ\;-?CZ
M=T%%%%8G*%?G+_P<6_L.ZW^T?^S]H'Q`\*:?<:IK?PV>X:_L[="\UQILP0RR
M*HY8PO$C;0/N/*?X<']&J,'.::8'\@>._%?67[,/_!;#]H3]EC2K+2M-\71>
M)]`T]%C@TKQ);_VA#$BC"HLN5N%0#@*LH4#H*_6S]LW_`(()?!3]J_6;W7M+
M@O/AQXJOF:6:\T-$^QW4IZO+:-\A)/),1C+'))))-?`'QM_X-F/C7X&\Z?P;
MX@\'^.[5,[(O.;2[V3T^24&(?]_J;:`]K^"7_!TSI\WDV_Q'^%=Y;8QYM]X;
MU%9MWKMMIPF/QG.?;J?M']F'_@L=^S[^U;J=KI>A>-X=%U^\8)%I.OPG3KF1
MCT5&?]U(QZ!4D9N.G3/\_P!\>?V#_C)^S'#-<>._AOXK\/V,#;7OY+)IK!23
M@#[3'NA))]'YKR7Z4^4#^OSOUZ5F^,?!^E_$'PGJ>@ZW8V^IZ/K-K)97MI.N
MZ*YAD4JZ,/0J2*_(/_@WZ_X*H^)-6^)%G\"OB%K-UK=AJ<##PGJ%[*9+BREB
M1G-DSGEHFC4F/<<H4"#(90G['5`'\P7_``4K_8<U/]@/]J;6?!EQ]HN=`N?^
M)CX>OY!S>V$C-LR1QYB$-&_3YD)P`PK%_8J_;G\<_L'>/=9\0^![N**XUS1[
MC2;F&==\+;T/DS;3QYD,NR121SM*GY78']YO^"PO_!/N']OC]EB[M-+MX?\`
MA/?"(DU/PW.1AI7VCS;,G^[.BA1T`D6)CPI!_FWN+>2SN)(9HWBEB8HZ.I5D
M8'!!!Z$'M5+4"34M2N-9U&XO+R>6ZNKN1IIII6+O*['+,Q/)))))/4FOV<_X
M-QO^"=H\$^#Y?CWXKL=NK:]%)9>%(9D&ZULR=LUY@\AI2&C4X!\M6(RLHK\\
M/^"5G[!E[^W_`/M5:7X:FCN(O"&C;=3\37<>5\JS5A^Y5ATEF;$:]P"SX(0B
MOZ7=!T&R\+:%9:7IMK!8Z=IL$=K:VT*!(K>)%"HB@<!54``#H!1)@6Z_FJ_X
M+8_\I1_B[_V$+7_TAMJ_I5K^:K_@MC_RE'^+O_80M?\`TAMJ2`9_P2G_`&)[
M#]OCXE?$KP+/(EMK$7@&[U30+MR0EIJ,5]8")FQ_`RN\;<'"RL0,@5\W^-_!
M6K?#;QCJGA_7M/N=*UO1+J2QOK.==LMM-&Q1T8>H8$<5^A?_``:__P#)_7B_
M_LG]Y_Z<=-KV;_@XZ_X)RBYMU_:!\)61\Z(167C"WA3[Z\1P7W'<?+$_MY1X
MPQIWLP/:O^"`'_!1H_M0_`H_#+Q3?"7QU\.[6..VEE?,FKZ6,)'+SRTD)VQ.
M>X,3$DLQ'AW_``=:'_D@O_<P_P#N+K\O?V9?VBO$?[*'QS\.>/\`PK<?9]9\
M.W0G16)\NZC/RR02`=8Y$+(P]&.,$`U^@?\`P<(_M(^&_P!K;X#_`+,?Q!\*
MW!FTCQ%:Z_-Y;D>;9RC^S%EMY`.DD;AE/8E<C(()+:@?`_['/_)W?PK_`.QP
MTG_TMAK^K6OY2OV.?^3N_A7_`-CAI/\`Z6PU_5K1(`K^=K_@X/\`^4H_C7_L
M'Z7_`.D,-?T2U_.U_P`'!_\`RE'\:_\`8/TO_P!(8:2`X_\`X(G?\I1_A%_V
M$+K_`-(;FOZ5:_FJ_P"")W_*4?X1?]A"Z_\`2&YK^E6A@%?R]?\`!4'_`)2*
M?&K_`+'#4?\`T>U?U"U_+U_P5!_Y2*?&K_L<-1_]'M0@(_\`@GQ^W+JW_!/K
MX\3>/-&T+3O$5Y+I4^E&UO9GBC"RO&Y?*<Y'ECCW-?;?_$4UX_\`^B5^#_\`
MP8W/^%?!G[&'[&/C#]NWXO2^"/!$NC1:S%I\NIL=3N7@A\J-D5AN5'.[,BX&
M/7FOJS_B&E_:*_Y_?AO_`.#F?_Y'IM(#T?\`XBFO'_\`T2OP?_X,;G_"OB3_
M`(*#_MRZM_P4%^/$/CS6="T[P[>1:5!I0M;*9Y8RL3R.'R_.3YAX]A7TI_Q#
M2_M%?\_OPW_\',__`,CU\I_MG_L8^,/V$OB]%X(\;RZ-+K,NGQ:FITRY>>'R
MI&=5&YD0[LQMD8].:$D!N?\`!+[_`)2*?!7_`+'#3O\`T>M?=_\`P=3_`/(_
M_!C_`+!^J_\`HRUKX0_X)??\I%/@K_V.&G?^CUK[O_X.I_\`D?\`X,?]@_5?
M_1EK0]P/RF\.:J-"\0V%^T9E%E<QSE`<%MK!L9[9Q7[$_P#$5/X?_P"B,:Q_
MX4<?_P`CU^..D:9)K6K6ME"4$UW*L$>XX7<S`#/MDU]__P#$-+^T5_S^_#?_
M`,',_P#\CTV!]'_\14_A_P#Z(QK'_A1Q_P#R/1_Q%3^'_P#HC&L?^%''_P#(
M]?.'_$-+^T5_S^_#?_P<S_\`R/1_Q#2_M%?\_OPW_P#!S/\`_(]+0#]IOV-?
MVE(/VP/V9O"?Q)MM(ET&#Q3!+.MA)<"X>WV3R18+A5#9\O/0=:]/KQ'_`()R
M?L]Z]^RK^Q3X"^'WB=]/DU[PU:30W;6,K36Y9[F:4;695)&UQU`YS7MU2!\@
M?\%ZO^43WQ6_[A'_`*>+&OYPJ_H]_P""]7_*)[XK?]PC_P!/%C7\X55$#^CW
M_@@K_P`HGOA3_P!Q?_T\7U?7]?('_!!7_E$]\*?^XO\`^GB^KZ_J0/D#_@O5
M_P`HGOBM_P!PC_T\6-?SA5_1[_P7J_Y1/?%;_N$?^GBQK^<*JB!^Y?[(WQ-N
M/@__`,&T%QK]I,;>\M_#/B*VMI@VUH99]5OK>-U/]Y7E!'N!7X:5^T?PGT"X
M\1_\&L]W;VPW21Z-JMT1@GY(?$-Q,_3_`&4:OQ<IQ`_=S_@V6^#=GX._8K\0
M^,3$IU3QIXBEC>7;@_9K2-8XD]\2/<'/3Y\=N?T@KX4_X-T/%5MXB_X)G:-9
MP,AET'7=2L;@!LE7:47`!X&#LG3CGC!SS@?==0V`5POQK_9D^'O[2$.G1^/O
M!GASQ@FD-(UD-5L8[H6AD"[RFX';NV)G'7:/2NZK!\>_%/PQ\*M/@N_%'B/0
M?#=K=2>3#-JFH16<<KX)VJTC*"V`3@<X%`'E$/\`P3$_9XMYDDC^#'PZCDC8
M,K+HD`92.A!V\&O=:\X_X;&^$/\`T53X;_\`A2V7_P`<KT6&9+F%)(W62.0!
ME93E6!Z$'N*`'4444`%?/7[;?@%O-TWQ)!&2NW[%=$#IR6C8_7+#/^[7T+6;
MXM\+6?C7PW>:5?1F2UO8S&X'5?1A[@X(]Q33LQ-'R5\$;J6YBO[)(Y9%A`N/
ME4L$'"DG'3G;7TC\%O%2ZKH1T^5Q]HL?N@]6C)X/X'C\J\R^#?A.^^`6E_$G
M4M0C!FT&P,L#C(2X1(Y9=PXZ':GK@Y'45E?#7]JZQU=;/5-1TB"5V&[[78'R
M9?0ATSM8]CR*^<SSB[+<JQ%/#X^;BYIM.S:TTUM=J_I;NS)UHQDH-ZO4^F**
MY;P?\:/#7CC8ECJD`N'X%O.?*ESZ`-][_@.:ZFO7P>/PV+IJMA:BG%]8M-?@
M:II[!11176,****`"BBB@`KD_BY\)](^*WA6XM=1TJVU"YCB<VC/(8)$DP=H
M$H5B@)QGY6'JK=*ZRC-5&<HOFB[-&E*K*G-3@[-?UT/RW_86\.>%/%W[:UC?
MZ-JD5C'X2N+V;7/#NK/'::UH%Q!%*CH\.2)HDFP/-@+J!C<(R<5]^?LA?M2^
M'/VS?V?/#WQ#\+M+'I^MQ'S;64@S6%PA*RV\F/XD<$9Z,-K#A@:_'S_@OA\%
MC\)OVZ+GQ'HDDNG3>*]*MM>66U<Q/#<*7MI2"N"&;R0Y(ZF0GKFNM_X-M?VF
M;CP%\<O$GPFO[ESI/C.U;5=+B9LK#?VR$R!1V\RW#%CS_P`>R>]?/2XGQ%?'
M1PN+M>-XW77^5V[OKZG](<5^&-+'<+_ZV9?4<DZ=.HH/[,5S>UC?[7*W=.R:
M4&G=NY^T5%%%>^?S6%?B9_P5>_X*O_M)_LJ?M\^/?!/A;Q^=$\,:9):2Z7:?
MV#IEP$AELX)<B2:V9V^=WR2QP01VK]LZ_,K_`(.#?^"8^L_M'^'M/^+_`(!T
MV75/%/A6Q-EKFF6R;I]2L$9I$FB4<O+"6<%>6=&&.8PK-`>%?\$E_P#@M1\8
M/B]^W!X7\'_%WX@P:MX6\5)-IL$<NCZ?9)'?,F;8^9!#&^7D41`9(+2@8Z$?
MM57\@T<DEI<*Z,\4T39#`E61@>OL0:^[OV;_`/@X@^/OP)\-6>BZS)X?^(FG
MV2+''/K\$IU!4&,*;B)T,AQ_%*'8YY)IM=@/Z"+BWCO+>2&:-)8I5*.CJ&5U
M(P00>"".U?SW_P#!P3^S5X%_9M_;:LH?`MA8Z+;>)]"BUC4-*LU5+>RN6GFC
M+1QKQ$KK&K;```=Q&`<#O_B1_P`'._QG\2Z3+;>'/"'@/PS+,NW[6T-Q?3PG
MGYD#R"//3[R,..ASQ^?OQ?\`C%XH^/OQ$U/Q;XRUN^\0^(M7D\R[OKI@7D(&
M````JJH``50%4`````4D@/2/^":JW[?\%"?@F--,GVC_`(3;22VP@'R?M<?G
M=>WE;\^V:_J.K\5?^#=G_@F_K7B/XJ6WQY\6:;<:?X=\/QRQ^%X[B)D;5;J1
M&C:Z4$?-#&C.`PX,A&#F,U^U5#`*_D;^(?\`R/\`KG_80N/_`$8U?UR5_(W\
M0_\`D?\`7?\`L(7'_HQJ<6!^IW_!JQ_R/_QGZ?\`(/TK_P!&W5?LM7XT_P#!
MJQ_R/_QG_P"P?I7_`*,NJ_9:DP"OYJO^"V/_`"E'^+O_`&$+7_TAMJ_I5K^:
MK_@MC_RE'^+O_80M?_2&VH0'O'_!K_\`\G]>+_\`LG]Y_P"G'3:_<WQ7X5TW
MQUX7U'1-8LK?4M(U>UDLKVTG0/%<PR*4>-@>JLI((]#7X9?\&P'_`"?SXO\`
M^R?WG_IQTVOW=HEN!_,;_P`%/?V#M3_X)_\`[46J>%G2>?POJ9;4?#=^_/VJ
MR9CA&;O+$?W;],E0V,.N?!KKQ=J=]X3L="FO9Y-(TR[N+ZUM"V8X)ITA2:11
MV+K;P`_]<UK^D[_@K!^P#8_\%`/V7+_1+>&&/QKX=$FI>&+ML*4N@OS6[,>D
M4ZC8W8,(W.=@%?S5Z[H=[X7UN]TS4K6>QU'3IWMKJVG0QRV\J,5=&4\AE8$$
M'H0:J+`[S]CG_D[OX5_]CAI/_I;#7]6M?RE?L<_\G=_"O_L<-)_]+8:_JUI2
M8!7\[7_!P?\`\I1_&O\`V#]+_P#2&&OZ):_G:_X.#_\`E*/XU_[!^E_^D,-)
M`<?_`,$3O^4H_P`(O^PA=?\`I#<U_2K7\U7_``1._P"4H_PB_P"PA=?^D-S7
M]*M#`*_EZ_X*@_\`*13XU?\`8X:C_P"CVK^H6OY>O^"H/_*13XU?]CAJ/_H]
MJ$!](?\`!M+_`,I%+W_L3[__`-'VM?OK7X%?\&TO_*12]_[$^_\`_1]K7[ZT
M2W`*_`K_`(.6O^4BEE_V)]A_Z/NJ_?6OP*_X.6O^4BEE_P!B?8?^C[JB.X'S
M?_P2^_Y2*?!7_L<-._\`1ZU]W_\`!U/_`,C_`/!C_L'ZK_Z,M:^$/^"7W_*1
M3X*_]CAIW_H]:^[_`/@ZG_Y'_P"#'_8/U7_T9:TV]0/RQ^'G_(_Z'_V$+?\`
M]&+7]<E?R$65[+IUY#<0.T<T#B2-QU5@<@_G7T5_P]X_:7_Z+'XP_P"_T?\`
M\31(#^FVBOYDO^'O'[2__18_&'_?Z/\`^)H_X>\?M+_]%C\8?]_H_P#XFE8#
M^FVBOR/_`.#>W]M_XL_M0_M,>-=(^(/CO7?%>F:?X8-Y;6]](K)#-]K@3>,`
M<[68?C7ZX4-`?('_``7J_P"43WQ6_P"X1_Z>+&OYPJ_H]_X+T_\`*)[XK?\`
M<(_]/%C7\X5.+`_H]_X(*_\`*)[X4_\`<7_]/%]7U_7R!_P06_Y1/?"G_N+_
M`/IXOJ^OZD#Y`_X+U?\`*)[XK?\`<(_]/%C7\X5?T>_\%Z?^43WQ6_[A'_IX
ML:_G"JHL#^A[_@C9\.;#XP?\$3O!GA+559M+\4:7X@TF[``)\J?4]0B?&>^U
MC7X#_&;X3:S\"/BQXC\&>((#;:SX8U";3;M,':7C<KN7/5&`#*>ZL#WK^A?_
M`((+?\HGOA3_`-Q?_P!/%]7A_P#P71_X)"7_`.U#!+\7/AI8_:?'>EV@BUG1
MH8\R^(+>,822+'WKF-?EV]9$"J/F55=)V`^4O^#>#_@H+I/[-7QAUGX9^,=2
MBTWPQ\098IM.N[APEO8ZH@V!7)X59TVIN/1HHAP"2/W<K^0F_L)]+OI[:YAF
MMKFV=HI894*21.I(96!Y!!!!!Y!KZI_9O_X+6_M$?LR>&[30]*\:#7M"L$6.
MVL/$%HFH+`B\!%E;$P0``!1)M`&`!3:`_I-K\,/^#DO]L[3/C5\??#WPP\.W
ML-]IWPX2>35IH6#1MJ4VT-#D<$PQH`<'AY9%(RE>-_';_@O+^TA\=?#-QH[^
M++'PEI]XACN!X<L193R+W`G)>9/K&Z_E7QP6>XF+,7DDD;))Y9B3^I)H2`[;
M]FCX*WW[1O[07@SP+IR2-=>*M7M].W)UBC>0"20^R1[G)[!37]7]E9Q:=9PV
M\"+%#`@CC0=%4#`'X"OR\_X("?\`!*75?@.@^-?Q&TR33O$VJ6;0>&M*N$*S
MZ7;2KB2ZE4\I+*AVJAY6-GW<OA?U(I-@%%%%(`HHHH`\K_;6\0?\([^R]XNF
M!.^>V2T51]YS+*D>!Z\,?PK\_O!7C>^^&.L&SU2VN[:VGVO+#-&R21A@"L@4
MC/((/N,>U?JE+`LI7>BOM8,,C.#Z_6O,OVEOV5]`_:1\/^7?(+#6K5"MEJ<2
M`RP]PC_WX\_PGIDD$$FOS+CW@>OG4EBJ%3WH124&M'JV_>OHW=6TMIJ]=/(S
M#`U:DU6I2LTM%W/E>PUBWO8X+J(Q75L^'&&.R1<],CD9Z<<U]:?`;XN>'?&N
M@0:=IC&PO+5,-83SM)(!W*,Q)=??J.X%?GUX[\(^-/V1?%K:7X@L9'TZ=R89
M4):UNP/XXGQPWJIP1W'0UTWA7XB6NOQQ7NE7CQSPD.-CE)H&'0G'(/H1^!K\
M=X<SK&\+XZ?/2NGI*+5I?)VNOR?;9KDP^9<LG&:M);I_H?I'FBOE7X5?MRW_
M`(>$5EXIMWU2U7Y1>0@+<H/]I>%?]#]:^A?A_P#%[PY\3[59-$U6UO'V[F@W
M;)X_]Z,X8?7&/>OZ(R+B_+,VBOJU2T_Y9:2^[KZJZ/8H8RE5TB]>W4Z6BBC-
M?3G4%%&:*`"HYED:%Q$Z)(5.QF4LJG'!(!&1[9'X4AU"W%\+4SPBZ:,RB'>/
M,*`@%MO7&2!GIDUYM^U/^U7X7_9.^'-SKNOW*R7;HPT_3(G'VG49>R(.R@D;
MG/"CU.`>C#82MB*L:%"+E*6B2W9Q8[,L-@L//%XJHH4X*\FWHO7_`"Z['Y`?
M\%=_V@]?^/7QKL]%\6>&H/#7B7P!:3Z-J4<$AD@O)#(76XA+?,(I(RCJK9(#
M?>;.:\!_X)\^*)OAG^W-\)=7@D>$1^*;"VE=<Y$,\RP2CCKF.1QCO7U)^V.]
M[^WI^SK:_&33](CD^('AF]_X1[QA8:;"Q,MO-(387:QC+;0&,!/+,P'9:\C_
M`&8/V!_CW>?%#PQXHT#X2>(;L^'M4M=5B368?[*M;KR9DE"E[AH\HVW!*G."
M<<U^8\1Y/F&6YY/"8F+<X26J5[K2ST6NG4_T3\,.->$N(_#&AC\!5IT:%2E.
M'+*:BHS:?/&\Y:>\[I-NR:3/Z`\T5@?#/7==\2^"+"]\2^'U\,:W.F;K34OD
MODMGST$R`!QWS@?2M^OT2,KI-'^?U:E*E4E3E9M-K1IK3LTVFNS3:?1A1^=%
M%49'R;^V-_P1;^!G[96JW6M:GH-QX4\5799Y=9\.R):37+G^.:(JT4I)Y+%-
MY_O#K7Q1XZ_X-6[^.ZFD\,_&2TFA;F*'4_#[1.G(X:2.=@W&3D(.PQWK]B:*
M:8'XS^%_^#5SQ'<W*?VU\8M$LH0WS?8M`EN6*X[;YHQDGCVZ\]*^I?V7/^#>
M'X$_`'6;75_$<>K_`!,U>U99$76V1-.1P<AA:Q@!Q_LS-(OM7WG11<"*RLX=
M.LXK>WABM[>W01Q11J$2-0,!5`X``&`!TJ6BBD`5^:>M_P#!L1\)-=UF\OI/
M'_Q&22\F>=E5K+:I9BQ`_<=.:_2RBG<#Y:_X)U_\$I?!O_!-W6?%5]X5\1^)
MM=D\60VT%RNJF`K"(6D92GEQKR?,.<YZ"OJ6BBD`5\&_M8?\$`OAM^US^T+X
MF^(VM>,_'&F:IXHGCGGMK(VHMXBD,<0"[XF;&(P>2>2:^\J*`/CW_@GW_P`$
M:/`G_!._XRZGXV\,>*?%NMZAJFBRZ))!JAMS"D4D\$Q<>7&IW!K=1UQACQTK
M["HHH`*^&_VR/^""GPI_;'^/6J?$&^UOQ3X6U77(XSJ%OI!MUM[J=1M,Y$D;
M$.RA0V#@E=W4DG[DHH`_.;X7_P#!M?\`"KX5?$SPYXHLO'?Q!N;OPWJ=MJD$
M4S6?ERO!*LJJV(0=I*`'!!QFOT9HHIW`*^(/VUO^"%7P\_;A_:%U;XC>(/%_
MC32-4U>&W@DMM.-L+=!#"L2D;XF;)"`G)ZU]OT4@/@W]D_\`X(!?#;]D;]H7
MPS\1M%\9^.-3U3PO/)/!;7IM3;REX9(B&V1*V,2$\$<@5]Y4447`*_/G]H/_
M`(-V?AA^T3\;_%?CO5/&_CRQU'Q;J<^J7%O:FT\F%Y7+%4W0EMH)XR2:_0:B
MBX'QG^P7_P`$4_`7_!/[XX2^._#7BOQ?K6HS:9-I9M]3-L8`DKQN6_=QJVX&
M,8YQR:^S*,T4`%?&?[>G_!%/P%_P4!^.$7COQ+XK\7Z+J,.F0Z6+?3#;"`I$
M\CAOWD;-N)D.><<"OLRB@#\^?V?/^#=GX8?L[?&_PIX[TOQOX\OM1\):G!JE
MO;W1M/)F>)PP5]L(;:2.<$&O8?\`@HI_P2E\&_\`!2+6?"M]XJ\1^)M"D\)P
MW,%LNE&`+,)FC9B_F1MR/+&,8ZFOJ6BG<#\R?^(7+X0_]%"^)'_?5E_\8H_X
MA<OA#_T4+XD?]]67_P`8K]-LT47`_,G_`(A<OA#_`-%"^)'_`'U9?_&*/^(7
M+X0_]%"^)'_?5E_\8K]-J*+@?(__``3U_P""/G@C_@G1\3-;\4>%_$_BO7+O
M7-,_LN6+5#;F*-/-27<OEQJ=V8P.3C!-?7%%&:0'F/[8W[+FD?MH_LX>(_AI
MKVHZEI6D^)?LWGW5AL%Q%Y%U#<KMWJR\M"H.0>">^#7PO_Q"Y?"'_HH7Q(_[
MZLO_`(Q7Z;9HIW`\Q_8Y_9<TC]B[]G#PY\--!U'4M5TGPU]I\BZO]AN)?/NI
MKEMVQ57AIF`P!P!WR:].HHI`>8_MC?LN:1^VC^SAXC^&FO:CJ6E:3XE^S>?=
M6&P7$7D74-RNW>K+RT*@Y!X)[X-?"_\`Q"Y?"'_HH7Q(_P"^K+_XQ7Z;447`
M\Q_8Y_9<TC]B[]G#PY\--!U'4M5TGPU]I\BZO]AN)?/NIKEMVQ57AIF`P!P!
MWR:].HHH`^9OVS?^"1_P3_;@O9]5\4>')-(\53+M/B#0Y19W\F!@&7AHICT&
M949@``"!7PM\0_\`@U<F%Y++X3^,436[$^7;ZMH!#QC(P#+%-AN,\B,=!QSQ
M^P5%-,#\;?!G_!JWK<]VA\0_&+2K2W5_F33M`DN'=>.`TDR!2>><'&!US@?:
MO[&7_!$KX'_L::S::]::1=^,O%MDPDAUCQ`Z7#6D@_C@A55BC(."&*LZXX?K
M7U[10V`?G11FBD`4444`%%%%`!1110!C^-_`6C?$GPY/I&O:;::KIMR,/!.F
MY<XP&'=6&>&!!'8BOB?]H'_@EQKOA#4)=<^%VHRWL29?^R[F81W47?$4IPL@
M[;7VG`ZN37WA17A9UPW@,TARXJ%VMI+22^?Z.Z\CCQ>`HXA6J+7NMS\BI/B]
MJO@76I-&\8Z1?:;J-J=DOF0&&5/=HVQ^8X]!73Z'XYM-6*7.E:@CRQG<K0R%
M9(SZX^\IK](_BK\#_"7QOT8V'BK0-.UJ``A&GCQ+#GO'(,.A]U(KY'^,7_!&
M33KVXEO?A_XKNM'GSNCL]44S1`YZ+,F'11[JY]Z_(,U\+<71DZF!ESK[G]ST
M^Y_(^;Q638J&M)\Z^Y_Y&!X._;1^('@-4C36!JMM'TAU&,7&?^!\2?\`CU>D
M>'_^"GTUN%36/"<4I'WI;.]*#\$=3_Z%7RC\0/V0_P!H7X*N_F>'+WQ+8QG"
MS:;C4Q)COM3]^!_O**\EUGX[ZWX3U!K/7?#DMG>)]^&426LB_P#`7!(KSZ.8
M\397^[=2:2Z25_NYT_P/'J9CF.&TO)>J_P`S]+;7_@J%X)\K-UH?BF)_2**"
M0?F95_E71_"']N[P[\<?B-9>&]`T/Q'Y]RCRR3W4<,<5NB*26;;(YQT`]2P'
MO7Y0S?M-V94EM+NE;T$JD?R%>R_L2_\`!2/P-^S]XCUV7Q'H?B**76;=+2#4
MK`0SO8IDELQN5R"VTD@G[@^4U]-DG%^;U\93IXR<84[^\^5;?+OMMH:8/B/&
MSKQC6DE"^KLNG3Y['H/[7?[4^OV_[9FH^(/"6KRZ?)X6A;0K.6,+(CJN1/E&
M!1P92Y&01\B'J!CYD^-/CBY\57USKGBO6+S5]1G',MU*9II`,X5<GA1G@#"C
MVKVB+]G+1/V@;MYOA'\7_"'BBXNR7_LK52VEZT6)^Z(YL^:V>K`*,_45X)\?
M?V7O'?P:OV/B_P`/:SI<;L$-[<Q-+;'G'$R;D;'HI)K^^N$L5D.*P]/^S:\)
MRC%1TLI-+UL][OU9_%O%^6<73QU;$Y[2J1H5*DJGNR<Z:<NTHMTTU&ROO96/
M(O`7[8GQ(_9B^(.K>(OA]K;^'+O4[)M.D'V>&Z3R2ZN#LE5D+AE!#;<C)`X)
M%?JG_P`$=?AA\:O$/AS4OBS\;?&/B[5=0\4VX@\/Z'J-VZ6UG9EE=KLVHQ&D
MDI"A/D#+&I/23`SOV'?^"-?@CP0^C>.O&VHZ9X_U*2..^TZVM1OT:$,`Z2Y/
M-SQ@@L%3G[AX-?>1SZ5^=\=<58'%2EAL!33D])5''5V^RFU>W=_):']7>%W!
M689=AZ=;,)N,(J\*2E=*_P!J23Y;]EKKJ]=!:***_+S]H"OSR_X+.V%MXO\`
MVO/V3_"FL>(]8\.>%?$^J:Y;:S+8ZL^F;X@NGD%I58`8).">FX^M?H;7YR?\
M%L=*\%ZY^V?^R#:?$1]$C\$W&K:\NL-J]PEO8B#9IN?-D=E55SCDD4`><?M^
M?`/P!^Q7\%D\??!#X[>/8?BA8ZG8V^@Z)!XV.L#Q!))=1H\!M<L\G[MV<KRI
M";2IW5^J'@V[U'4/"&DW&KVZ6FJSV<,E[`ARL,Y0&1![!LC\*_+'_@H=\.OV
M(/AY^R]XA\1?#/Q!\/-(^)FC1K/X6N?`WBA9]4CU`.#%A+:=CL)X9V7"C)!#
M`&OTA_93OO%6I_LQ_#RY\<QRQ>,[CPWI\FMK*-LJWAMHS-O&!A]^[<!P&R!Q
M3N!W]%%%(`KY,_X+E^(=0\*?\$M?BCJ&EWUYIM];_P!D^5<6LS0S1YU>R4[6
M4@C*D@X/()%?6=?('_!>K_E$]\5O^X1_Z>+&@#ZI\`2-+X$T1W9G=["`DDY)
M/EKS6M6/\/?^1`T/_L'V_P#Z+6MB@`HHHH`^;?\`@JS^UUK'[&O[(FH:]X6@
M2?QIXBO[?PWX<5E5PM]<EMK[6X8I&DKJI!!95!&W->5^"?\`@AWX.\2>`H+W
MXG^-OB9XN^)VHVZ3:GXD7Q1<Q/;79&2;9<[0B,<)YBMPHX'0=+_P6\^!GB7X
MQ_L70:IX1T^;6-?^&OB2Q\9V^G1(9)+U;42I(@4<MMCG=]HY(C(&3@'T3X,_
M\%//@;\9O@S9^-8/B3X/T6REMEFO;35=7@M+S2Y"N6AFC=@P=3D<`AL94L""
M0#RC_@F9\:O'7@?]H#XK?LV_$KQ#=^,=9^%OV?4/#_B&[RUWJND7"JR?:&)R
MTD8DARQ+',CJ6.P$_:E?!'_!-#6[K]KO]O?XX_M&Z?:W=I\/]5M;7P=X5FN(
MFB.KQ6_EF:Y"L`P7?"I&0/\`7%3\R-7WO0`4444`%?$'_!+#Q3JFO_MD?MAV
MU_J5_?6VF^/(XK2*>X>1+5-UW\L88D(.!P,#@5]OU^;W_!.[]HWX>?`G]MW]
ML2'QQX\\&>#9=2\?*]HFN:W;:<UTJ/=AC&)G7>%++DC.,CUI@?I#17%?"S]I
M7X<_'/4+NT\$>/\`P3XQN[",2W,.AZY:ZA);H3@,ZPNQ52>,G`S7:T@"BBB@
M#-\9>+++P%X0U77=2E\C3M%LYK^ZD_YYQ1(7=OP52:_.C]CG]D_4?^"MGA&Y
M^.OQU\1^,)M"\4:A<_\`"(^#=,UF:PTS2+"*5X5=A$59I2RN-P*E@H8E@X"_
MH3\6?`<?Q3^%GB;PQ+*8(O$>E76EO*!GRUGA>(M^`;-?#W_!'O\`:X\+?`_X
M!+\`OBAK6D^`?B;\)KZ[TNZT_6KI+%=0@:X>:*XMWE*K*A67`VG)"A\;64D`
MH6_AS7?^"2'[;GPN\,Z)XL\2^)?@=\;=0/AU=%UV_:^E\,ZH2JP-;2-R(W:1
M!M[C?NW,$(_1"OSO_:@^-6C_`/!0_P#X*)?`GX;?"[5+7Q3HGPD\1Q^/?%VN
MZ;(MQIUBUJR-;P+.N4=V8,A"DX,JC.5?;^B%`!1110`5\2_\%&/BCXZ^-7[5
M_P`./V8OA]XEO_!!\9Z;-XD\7^(;`F._LM(C=T6*W<'*-*\,J$CG)C!PA<'[
M:KX`_;O\1K^Q#_P5'^%_[0>NVMROPU\1^'9?`?B34X8FE7193,\T$\H`)",6
MC'R_PP28!;`8`O?%C_@B1X=\$?#2[UCX*>+_`(C^$/BMH=NUUH^K-XFGF&I7
M*#<(;E781[)2-I*A5!;)#*"A^NOV;=0\;ZI\"/"LWQ)T^TTOQX=/C37(+:6.
M6'[4ORNZ&,E-KXWX4D+OQVKXJ_X*-P?LB^/_``UK'Q4\1^,+3Q9XLO-+6WT7
M3_#7C29[G6)@C+;10VUK-R6<@%]N!G+&O4_^"$NHW&J_\$J?A9<75Q-<W$G]
MK;I)7+NV-8O0,D\G@`?A0!]<T444`%>>?M=7DVG?LH?$^YMYI;>X@\):K)')
M&Q1XV%G*0RD<@@\@BO0Z\X_;&_Y-$^*G_8GZM_Z134(#S_\`X).ZS>>(?^"<
MOPBO;^ZN;Z\N=!1Y9[B5I993O?EF8DD^YKZ'KYP_X)"_\HTO@Y_V+Z?^C'KZ
M/H`****`//?VL/CU;?LO?LV>-_B#=0"[3PGI$]_';EBHN9E7$41(Z!Y"BY[;
MLU\:?LJ?\$PHOVS?@OHOQ7_:)\5^.O%WC;X@6::S#80:Y<:?I_AZVN!YD$-O
M#"RA#Y1C9E/`8[=N06;ZG_X*'?`C4/VF?V)/B7X'TF,2ZOKFBRC3XB=HFN8B
M)H8\Y&-TD:KD\#//%>._\$S?^"C7PR\??LB>$-&\1^,/#G@WQEX$TJ#P_P"(
M-&UV_BTR[M+BSC6!I/+F924;8&R,A22IPRD`N!M?L'?L\?%[]DCXW>.?`VM:
M]JWC?X(FWBOO!NLZUJ276IZ;+E1)8."?,*`,V#M"?N00$+E:^KJ^4?V/_P!N
MK7?VS/VS/B7:>$8],U'X%>!]/BTZSUZ.U</JVLLT;/Y,Y;;)"B"4$*O>)L[7
M7=]74`%%%%`!7Y5Z_J7@;]KC_@IC\9?"/[2WQ'UCPEIG@N[M[+P/X4GU^30=
M+O+4JY:Z\P,@DF<>4X^8,1+CYU4*GZJ5\$I^T)\$?VO_`(\?$CX4_M,>#/AO
MX=\:^`];ELM#;7'2W?5M*/,$]M=2['#./G,:.,JZ$`X;#0':_L7_`+(OC?\`
M9$_:DU:U\'>*K[Q7^SAXDT-;NPM]4UK^T)]#U,2?<MR22860,21U\Q<Y*%C]
M@U^7?[,7A;P'^SG_`,%@_"/@G]FKQ5=ZO\./$/A_4+_QWH>G:NVL:-H[1PR?
M9YA*7<+(9A;J=S,R[PN<2;1^HE(`HHHH`****`"BBB@!"X!QS33,!GC-(V<'
MUJ"0D+R:`)C=*.H-,.H(O4&JD^XIE2`?>L+6FU((WV::W0]1N4F@#ICJD8[$
M_C5+7++3/$UF;;4K"SU"W/)BN85E3KZ,"*\F\63^/\L-.U?0X2.GFV[L/TKE
M;*;XQ"]S-XC\(-`3PJ6$P8#ZEJ;A=69+:>AZ+K/[(OP@\1S^;>?#+P+)+G)=
M=$MD9N,<E4!/`[UEV_[`_P`$(IY95^&'@]GF.6#V*.HY[*V0OX`5<\*S>,"%
M%_J6E3-CGRH64?K7<:6;LJOG21,?]D$5R2R_#-W=./W+_(Q>%H2U<%]R,OP5
M^SS\._AW<1R^'_`G@_1)XB"LMCH]O;R`@#G<J`D\#G.>*[.Y@AO[>2">*.:&
M52KQNH97!Z@@]156(G`R>:G0G`]*WITXP5H*WIH:QIQBN5))$/AWPWIWA+28
MM.TFPLM+T^`L8[:T@6"&,LQ9B$4`#+,S'`Y))ZFK],7[PI]:2DVVV[MCA!1B
MHQ5D@HHHI%!7'_%;]GKP!\>/L'_"<^!_!_C/^RO,^Q?V[HUMJ/V/S-OF>7YR
M-LW;$W;<9V+GH*["B@#S#PI^Q)\&/`?B&TU?0_A%\,-%U:PD$MM>V/A:QM[B
MV<=&21(@RL/4$&O3^E%%`!1110`5C^/?AYH'Q4\)W>@>*-"T?Q)H5_L^U:=J
MEE'>6EQL=9$WQ2!D;:ZJPR.&4$<@5L44`,M[:.TMXX88TBBB4(B(H544#```
MZ`#M3Z**`"BBB@`&>>*\4\:?\$W_`("_$/QO)XDUKX1^`]0UF>0RS7$FE1#[
M2YZM(@`61CW+@DU[710!4T'0+#PKHMKINEV5IING6,:PVUK:PK#!;HHP$1%`
M"J!T`&!5NBB@`HHHH`*\N\4?L/\`P6\;^([W6-;^$'PNUC5]3F:XO+Z]\*V%
MQ<W4K'+222/$6=B>22237J-%`'$_"S]FKX<_`S4+J[\$^`/!/@ZZOXQ#<S:'
MH=KI\EP@.0KM"BEE!YP<C-=M110`4444`%>;?'7]COX6?M-2V\OC_P``^%_%
M5S:+LANKZQ1[F%,YV+,`)`N>=H;!]*])HH`Y+X._`;P5^SYX:;1_`WA3P_X2
MTR1_,DM]+L8[99GQC>^P`NV.-S9..]=;110`4444`%4/$WA?3?&F@7>DZSIU
MAJ^E:A&8;JSO($N+>Y0]4>-P593Z$$5?HH`\=^&7_!/GX(?!GQROB7PO\*_!
M.BZ]$WF0WMOI<?FVK?WH<@^4>V8]IQ7IG@CP'H?PS\,V^B>&]%TGP]HUFTC0
M6&FVD=I:PF21I'*QQ@*I9W=C@<LQ)Y)-:U%`!1110`56UG1K/Q%I%WIVHVEM
M?V%_"]O<VUQ$LL-Q$ZE7C=&R&5E)!!!!!(-6:*`,SPAX-TCX>^&K+1=`TK3=
M#T;3H_)M+#3[9+:UM4SG:D:`*JY)X``YK3HHH`****`"O(OC!^P/\%OC]XM&
MO>,OACX.U_6R07O[C3D%Q/MZ"1U`,@`&`')&.*]=HH`QO`/P[T#X5^%;70O#
M&B:3X>T6Q&VWL--M$M;:$$Y.V-`%&3R>.36S110`4444`%>=_'/]DCX8_M,Q
MVX\?^`_"_BR6T&V"?4+!)+B!<YVI+CS%4GD@,`:]$HH`XGX)_LW>`/V;]#FT
HWP%X.\.^$;2Z*M<+IEC';M=%1A6E91ND8#/+DGFNVHHH`****`/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
